CoChat

Investigational glucagon-like peptide-1 agonists for the treatment of obesity

Tomlinson, Brian, Hu, Miao, Zhang, Yuzhen, Chan, Paul, Liu, Zhong-Min · 2016 · Expert Opinion on Investigational Drugs

The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

INTRODUCTION: Obesity is a worldwide problem predisposing to type 2 diabetes mellitus (T2DM), hypertension, cardiovascular disease, cancer and other comorbidities. Lifestyle modification is the first line intervention but adjunctive pharmacotherapy is often required. The GLP-1 receptor agonists (GLP-1RAs) were developed primarily for T2DM and they also reduce body weight. Liraglutide was approved for the treatment of obesity and other GLP-1RAs are likely to be suitable for this indication. AREAS COVERED: This review describes the GLP-1RAs that have been approved for the treatment of T2DM as potential candidates for the treatment of obesity and the new agents currently under development which may have advantages in patient adherence. EXPERT OPINION: The GLP-1RAs offer a welcome addition to obesity pharmacotherapy. They appear to be free of serious adverse effects although uncertainty remains about possible risks of pancreatitis and neoplasms. However, they have frequent gastrointestinal side effects, particularly nausea, which limits their tolerability. Cardiovascular outcome studies in T2DM support their use and this is likely to increase in both T2DM and obesity. Other GLP-1RAs which can be given by subcutaneous injection once weekly or less frequently or by oral administration would have advantages especially if nausea is less frequent than with liraglutide.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2016.1221925

Cites

104 of 105 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 105 references

Research works printed but not linked: 2

  1. Baron MA, Buse J, Azeem R, et al. A randomised, double-blind, placebo-controlled, 39 week trial of ITCA 650 as add-on therapy in type 2 diabetes. Diabetologia. 2015;58:S55–S55.
  2. Henry RR, Rosenstock J, Denham D, et al. Efficacy and tolerability of ITCA 650 (continuous subcutaneous exenatide) for 39 weeks in patients with poorly controlled type 2 diabetes mellitus and high baseline HbA(1c) (>10%). Diabetologia. 2015;58:S378.

Cited by

See all 28

Metadata

Authors
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M.
Affiliations
  • Tongji University (CN)
  • Chinese University of Hong Kong (HK)
  • Wan Fang Hospital (TW)
Corresponding author
  • Tomlinson, Brian
  • Chan, Paul
  • Liu, Zhong-Min
Venue
Expert Opinion on Investigational Drugs
Published
2016-08-26
Volume
25
Issue
10
Pages
1167-1179
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2508533215
Cited by
25
References
104
Citations by year
2026: 1 · 2025: 6 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 4 · 2017: 4 · 2016: 1
FWCI
0.42
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, GLP-1 receptor agonists, liraglutide, type 2 diabetes, obesity pharmacotherapy, weight loss, pancreatitis risk, neoplasms, nausea, gastrointestinal adverse effects, subcutaneous injection, patient adherence, cardiovascular outcomes
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Body Weight, Diabetes Mellitus, Type 2, Humans, Obesity, Drug Design, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Investigational glucagon-like peptide-1 agonists for the treatment of obesity. https://app.cochat.ai/papers/10.1080/13543784.2016.1221925
The paper
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016). Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2016.1221925

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.